Skip to content

Research on the Use of Remimazolam Combined with Esketamine for Induction of General Anesthesia in Coronary Heart Disease Patients Undergoing Non-Cardiac Surgery

Research on the Use of Remimazolam Combined with Esketamine for Induction of General Anesthesia in Coronary Heart Disease Patients Undergoing Non-Cardiac Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087023
Enrollment
Unknown
Registered
2024-07-17
Start date
2024-07-18
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

Remimazolam combined with esketamine group (group RE):General anesthesia induction with remimazolam 0.2~0.3mg/kg and esketamine 0.3mg/kg
Propofol group(group P):General anesthesia induction with propofol 1.5~2.5mg/kg

Sponsors

The Second Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Conform to the international standards for clinical diagnosis and naming of ischemic heart disease; (2) Gender is not limited, age 18~75 years old, ASA grade II~III, NYHA grade I~II, BMI 18~30kg/m2; (3) Patients who are scheduled to undergo laparoscopic surgery (gastrointestinal/pancreatic/bile duct/liver malignancy) under general anesthesia; (4) Subjects voluntarily participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those who have contraindications to general anesthesia or are allergic to or contraindicated to the study drug; (2) Combined with valvular heart disease or atrial fibrillation; (3) poorly controlled or untreated hypertension; (4) Obvious abnormality of liver and kidney function; (5) Poorly controlled diabetes mellitus (fasting blood glucose > 11.1mmol/L); (6) Psychiatric or neurological disorders and a history of drug and/or alcohol abuse; (7) Pregnant or lactating women; (8) Those who are unable to obtain cardiac ultrasound images or whose image quality is poor and cannot be analyzed; (9) Unable to cooperate or refuse to participate in the participant; (10) Other conditions judged by the investigator to be unsuitable for participating in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Stroke volume(SV);

Secondary

MeasureTime frame
Left ventricular outflow tract velocity-time integral(LVOT-VTI);Cardiac output;Intraoperative analgesic drug dosage;Analgesic drug consumption 24 hours postoperatively;15-item recovery quality scores(QoR15);Athens Insomnia Scale score(AIS);Hamilton Anxiety Scale score(HAMA);The incidence of adverse reaction within 24 hours after surgery;Visual Analogue Scale Score;

Countries

China

Contacts

Public ContactJin Yanwu

The Second Hospital of Shandong University

jinyanwu_aa@163.com+86 176 6008 5535

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026